MiMedx sees FY25 revenue up at least high single-digits

The company said, “Provided that the future effective LCDs go into effect as currently planned, MIMEDX (MDXG) expects net sales growth of at least high single-digits as a percentage and Adjusted EBITDA margin above 20% for the full-year 2025. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%.”